국가: 뉴질랜드
언어: 영어
출처: Medsafe (Medicines Safety Authority)
Cefoxitin sodium 1 g
Teva Pharma (New Zealand) Limited
Cefoxitin sodium 1 g
1 g
Powder for injection
Active: Cefoxitin sodium 1 g
Vial, glass, single dose, Vial, powder for inj. 1g, 5 dose units
Prescription
Prescription
ACS Dobfar SpA
Cefoxitin Actavis is indicated for the treatment of the following infections when due to susceptible organisms (see Microbiology) peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, skin and skin structure infections. Cefoxitin Actavis has a high degree of stability against beta-lactamase and is therefore effective against beta-lactamase producing organisms resistant to penicillins or cephalosporins. It can also be used in mixed infections provided that the organisms are sensitive to it. Cefoxitin Actavis can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes, or anaerobes.
Package - Contents - Shelf Life: Vial, glass, single dose, Vial, powder for inj. 1g - 5 dose units - 36 months from date of manufacture stored at or below 25°C protect from light 36 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) 6 hours reconstituted stored at or below 30°C protect from light - Vial, glass, single dose, Vial, powder for inj. 1g - 10 dose units - 36 months from date of manufacture stored at or below 25°C protect from light 36 hours reconstituted stored at 2° to 8°C (Refrigerate, do not freeze) 6 hours reconstituted stored at or below 30°C protect from light
1993-03-30
Version 1.0 1 NEW ZEALAND DATA SHEET 1. PRODUCT NAME Cefoxitin Actavis, Powder for Injection 1g and 2g 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains cefoxitin sodium equivalent to 1 g or 2 g of cefoxitin. Each gram of cefoxitin sodium contains approximately 51.2 mg (2.2 mEq) of sodium. The pH of 10% w/v cefoxitin sodium in Water for Injections is 4.2 to 7.0. 3. PHARMACEUTICAL FORM Cefoxitin Actavis is a white to slightly yellow sterile powder of cefoxitin sodium for intravenous and intramuscular administration following reconstitution. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Cefoxitin Actavis is indicated for the treatment of the following infections when due to susceptible organisms (see MICROBIOLOGY) peritonitis and other intra-abdominal and intra-pelvic infections, female genital tract infections, septicaemia, endocarditis, urinary tract infections, respiratory tract infections, bone and joint infections, skin and skin structure infections. Cefoxitin Actavis has a high degree of stability against ß-lactamase and is therefore effective against ß-lactamase producing organisms resistant to penicillins or cephalosporins. It can also be used in mixed infections provided that the organisms are sensitive to it. Cefoxitin Actavis can be used as adjunctive therapy in the surgical treatment of infections including abscesses, infection complicating hollow viscus perforations, cutaneous infections and infections of serous surfaces whether caused by aerobes, mixed aerobes and anaerobes, or anaerobes. Cefoxitin Actavis is also indicated for the prevention of post-operative infections associated with certain surgical procedures of the gastrointestinal, biliary and genital tracts. 4.2 DOSE AND METHOD OF ADMINISTRATION TREATMENT Cefoxitin Actavis may be administered intravenously or intramuscularly (see reconstitution directions for each route below). Dosage and route of administration are determined by severity of infection, susceptibility of the causative organisms, and condition of the patient 전체 문서 읽기